Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

By Gilbert GREUB, B. Ledergerber, M. Battegay, P. Grob, for the Swiss Hiv Cohort Study. The Lancet, 2000

1,010 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/e211b2c37e3756f47dcc526ca1b9f7fa3c3ef259

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Weber
2. W. El-Sadr
3. N. Friis‐Møller
4. S. De Wit
5. M. Law
6. C. Pradier
7. O. Kirk
8. K. Sherman

Citations in the corpus

• Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. (2006, background): “0 CD4 cell count, median (range), /μL Nadir 19 (0-530) 102 (0-761) 108 (0-1150) Before death 40 (0-957) 196 (6-1200) 266 (0-1878) Previous AIDS before death, % 100.”
• Redefining chronic viral infection. (2009, neutral): “For example, HIV and HCV coinfection worsens the prognosis of both infections (De et al., 2002; Greub et al., 2000).”
• Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. (2002, background): “At least 1 study suggests that HCV may blunt the T cell response to effective antiretroviral treatment [28].”